SCHEMBL1865773

SCHEMBL1865773

O=C(NNC(=O)c1ccc(Cl)s1)c1cccs1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.62
TP53 P04637 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
HPGD P15428 2/20 0.60
TSHR P16473 1/20 0.60
MAPT P10636 5/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
ALDH1A1 P00352 7/20 0.56
GAA P10253 5/20 0.56
LMNA P02545 2/20 0.56
NPC1 O15118 3/20 0.56
TDP1 Q9NUW8 2/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MDM2 Q00987 1/20 0.56
HDAC1 Q13547 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1858111 0.84 RAB9A (0.78) RAB9ATP53L3MBTL1MAPTSMN1; SMN2
SCHEMBL1861604 0.81 HDAC1 (0.61) RAB9ATP53L3MBTL1MAPTSMN1; SMN2
SCHEMBL1861725 0.80 RAB9A (0.62) RAB9ATP53L3MBTL1TSHRMAPT
SCHEMBL1867882 0.78 GAA (0.64) RAB9ATP53L3MBTL1HPGDTSHR
SCHEMBL1865862 0.78 GAA (0.54) RAB9ATP53HPGDTSHRMAPT
SCHEMBL27572930 0.77 F2 (0.52) RAB9ATP53HPGDMAPTSMN1; SMN2
SCHEMBL4739925 0.77 RAB9A (0.73) RAB9ATP53L3MBTL1MAPTSMN1; SMN2
SCHEMBL15988680 0.77 HPGD (0.77) RAB9AL3MBTL1HPGDTSHRMAPT
SCHEMBL8345583 0.76 RAB9A (0.62) RAB9ATP53L3MBTL1TSHRMAPT
SCHEMBL5903862 0.75 RAB9A (0.57) RAB9ATP53L3MBTL1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105597-A1 Modulation of pathogenicity QUONOVA, LLC 2011-05-05 US disclosed
US-20110105597-A1 Modulation of pathogenicity QUONOVA, LLC 2011-05-05 US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
EP-1478364-B1 SELECTIVE ANTIBACTERIAL AGENTS QUONOVA LLC (US) 2009-09-16 EP disclosed
EP-1478364-B1 SELECTIVE ANTIBACTERIAL AGENTS QUONOVA LLC (US) 2009-09-16 EP disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 US disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 US disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 US disclosed
US-20080182878-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-31 US disclosed
US-20080182878-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-31 US disclosed
US-20080182878-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-31 US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 US disclosed
US-20040063765-A1 Modulation of pathogenicity 4 SC AG (DE) 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076012-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 RAB9A 4031/4885TP53 2829/4885L3MBTL1 1128/4885
US-20110105597-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 RAB9A 4032/4885TP53 2809/4885L3MBTL1 1152/4885
US-20100280036-A1 Modulation of Pathogenicity NR4A1, NR4A2, NR4A3 RAB9A 4032/4885TP53 2809/4885L3MBTL1 1152/4885
US-20080182878-A1 Modulation of pathogenicity NR4A1, NR4A2, MSR1 RAB9A 4013/4885TP53 2827/4885L3MBTL1 1149/4885
US-20080176938-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 RAB9A 3999/4885TP53 2880/4885L3MBTL1 982/4885
US-20040063765-A1 Modulation of pathogenicity NR1H4, NR4A1, MSR1 RAB9A 3056/4885TP53 3787/4885L3MBTL1 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.